Business
SINGAPORE, May 18, 2026 /PRNewswire/ -- AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets,...
From LinkedIn regarding Techcyte and Biobase partnership Sam Seymour, CPO and Co-Founder at Biobase: I started in digital pathology over 6 years ago at Paige (now Tempus AI). Not a lot has changed since then; digital pathology's adoption...
Agreement includes a license for Owkin AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly...
Regarding the Roche acquisition of PathAI, from Elizabeth Bourn on LinkedIn: This morning, Roche announced that it had entered into a definitive merger agreement to acquire PathAI for $750M upfront, with up to $300M in additional milestone...
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong position in...
Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced the completion of a $15 million capital raise led by Van Tuyl Companies, with participation from existing investors Zoetis Inc....
